Zacks Investment Research upgraded shares of Natus Medical Incorporated (NASDAQ:BABY) from a sell rating to a hold rating in a research note published on Friday.

According to Zacks, “Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories. “

Separately, BidaskClub lowered Natus Medical from a sell rating to a strong sell rating in a research report on Thursday, August 24th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $44.50.

Natus Medical (NASDAQ BABY) traded up 2.32% during midday trading on Friday, reaching $35.35. The company had a trading volume of 305,084 shares. The stock has a 50-day moving average price of $33.93 and a 200 day moving average price of $36.05. Natus Medical has a 12-month low of $31.65 and a 12-month high of $44.39. The company has a market capitalization of $1.15 billion, a PE ratio of 61.27 and a beta of 0.96.

Natus Medical (NASDAQ:BABY) last announced its earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.33 by $0.01. The business had revenue of $122.20 million during the quarter, compared to analyst estimates of $121.99 million. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. Natus Medical’s revenue for the quarter was up 27.3% compared to the same quarter last year. During the same period last year, the company earned $0.39 EPS. Equities analysts forecast that Natus Medical will post $1.70 EPS for the current year.

WARNING: This report was originally reported by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.watchlistnews.com/natus-medical-incorporated-baby-upgraded-to-hold-by-zacks-investment-research/1583026.html.

In other news, Director Robert A. Gunst sold 4,400 shares of Natus Medical stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $35.17, for a total value of $154,748.00. Following the completion of the transaction, the director now directly owns 50,850 shares of the company’s stock, valued at approximately $1,788,394.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director William M. Moore sold 3,000 shares of Natus Medical stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $34.10, for a total value of $102,300.00. Following the completion of the transaction, the director now directly owns 30,410 shares of the company’s stock, valued at $1,036,981. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Ameritas Investment Partners Inc. bought a new position in shares of Natus Medical in the 1st quarter worth about $110,000. Riverhead Capital Management LLC raised its position in shares of Natus Medical by 90.9% in the 2nd quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock worth $107,000 after acquiring an additional 1,364 shares in the last quarter. Sei Investments Co. raised its position in shares of Natus Medical by 29.7% in the 2nd quarter. Sei Investments Co. now owns 3,182 shares of the medical equipment provider’s stock worth $119,000 after acquiring an additional 728 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Natus Medical by 94.0% in the 1st quarter. Victory Capital Management Inc. now owns 3,184 shares of the medical equipment provider’s stock worth $125,000 after acquiring an additional 1,543 shares in the last quarter. Finally, Flinton Capital Management LLC raised its position in shares of Natus Medical by 82.0% in the 2nd quarter. Flinton Capital Management LLC now owns 3,774 shares of the medical equipment provider’s stock worth $141,000 after acquiring an additional 1,700 shares in the last quarter. 92.65% of the stock is owned by hedge funds and other institutional investors.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.